NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, non-randomized, multi-site, phase 2 clinical trial of
neoadjuvant pembrolizumab in combination with gemcitabine-cisplatin for 2 cycles,followed by
concurrent pembrolizumab-cisplain-radiation, and then maintainence pembrolizumab monotherpy
given every 3 weeks for a total treatment duration of 12 months, in previously untreated
stage IVA ( UICC 8 th Edition ) nasopharyngeal cancer(NPC).